동아에스티 국산 26호 당뇨약 ‘슈가논’…글로벌 시장 저변 확대

Suganon, a Korean diabetes drug launched in 2015, is successfully competing globally against major pharmaceutical players by strategically expanding from single-drug therapy to multiple fixed-dose combinations. This approach reflects the broader industry shift toward combination-based diabetes treatment, enabling personalized therapeutic options for diverse patient populations. The product line extension demonstrates how domestic drug developers can establish competitive advantage in mature markets dominated by global pharma giants through targeted product innovation.